Familial Amyloid Polyneuropathy: A Clinical Scale for the Evaluation of the Peripheral Neuropathy
A considerable progress has been made in the recent past in understanding Familial Amyloid Polyneuropathy (FAP) which expectedly will contribute towards new therapeutical trials. Besides, the heightened concern for a disease whose progressive course leads to complete disability and death in about 10 years must also motivate therapeutical attempts. Under these circumstances, the need for a statistically tested scale as an empirical instrument for evaluating the trials seems quite justified. Such scales exist for other neurological disorders such as Parkinson disease1 and multiple sclerosis2.
KeywordsAutonomic Neuropathy Motor Neuropathy Familial Amyloid Polyneuropathy Partial Score Heighten Concern
Unable to display preview. Download preview PDF.
- 4.P. Coutinho, A. Martins da Silva, J. Lopes Lima, A. Resende Barbosa, Forty years of experience with type I amyloid neuropathy (review of 483 cases), in: “Amyloid and Amyloidosis”, G. G. Glenner, P. Pinho e Costa & Falcão de Freitas, eds., Excerpta Medica, Amsterdam (1980).Google Scholar